Importance: Health care was disrupted in the US during the first quarter of 2020 with the emergence of the COVID-19 pandemic. Early reports in selected samples suggested that cancer screening services decreased greatly, but population-based estimates of cancer screening prevalence during 2020 have not yet been reported.
Objective: To examine changes in breast cancer (BC), cervical cancer (CC), and colorectal cancer (CRC) screening prevalence with contemporary national, population-based Behavioral Risk Factor Surveillance System (BRFSS) data.
Design, Setting, And Participants: This survey study included respondents from the 2014, 2016, 2018, and 2020 BRFSS surveys who were eligible for BC (women aged 50-74 years), CC (women aged 25-64 years), and CRC (women and men aged 50-75 years) screening. Data analysis was performed from September 2021 to February 2022.
Exposures: Calendar year.
Main Outcomes And Measures: Self-reported receipt of a recent (defined as in the past year) BC, CC, and CRC screening test. Adjusted prevalence ratios (aPRs) comparing 2020 vs 2018 prevalence and 95% CIs were computed.
Results: In total, 479 248 individuals were included in the analyses of BC screening, 301 453 individuals were included in CC screening, and 854 210 individuals were included in CRC screening, In 2020, among respondents aged 50 to 75 years, 14 815 (11.4%) were Black, 12 081 (12.6%) were Hispanic, 156 198 (67.3%) were White, and 79 234 (29.9%) graduated from college (all percentages are weighted). After 4 years (2014-2018) of nearly steady prevalence, past-year BC screening decreased by 6% between 2018 and 2020 (from 61.6% in 2018 to 57.8% in 2020; aPR, 0.94; 95% CI, 0.92-0.96), and CC screening decreased by 11% (from 58.3% in 2018 to 51.9% in 2020; aPR, 0.89; 95% CI, 0.87-0.91). The magnitude of these decreases was greater in people with lower educational attainment and Hispanic persons. CRC screening prevalence remained steady; past-year stool testing increased by 7% (aPR, 1.07; 95% CI, 1.02-1.12), offsetting a 16% decrease in colonoscopy (aPR, 0.84; 95% CI, 0.82-0.88) between 2018 and 2020.
Conclusions And Relevance: In this survey study, stool testing increased and counterbalanced a decrease in colonoscopy during 2020, and BC and CC screening modestly decreased. How these findings might be associated with outcomes is not yet known, but they will be important to monitor, especially in populations with lower socioeconomic status, who experienced greater screening decreases during the COVID-19 pandemic.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166223 | PMC |
| http://dx.doi.org/10.1001/jamanetworkopen.2022.15490 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Whole-genome sequencing of cell-free DNA reveals DNA of tumor origin in plasma from patients with colorectal adenomas.
Mol Oncol
January 2025
Department of Molecular Medicine, Aarhus University Hospital, Denmark.
The presence of circulating tumor DNA (ctDNA) in patients with colorectal adenomas remains uncertain. Studies using tumor-agnostic approaches report ctDNA in 10-15% of patients, though with uncertainty as to whether the signal originates from the adenoma. To obtain an accurate estimate of the proportion of patients with ctDNA, a sensitive tumor-informed strategy is preferred, as it ensures the detected signal originates from the adenoma.
View Article and Find Full Text PDFBias in Prediction Models to Identify Patients With Colorectal Cancer at High Risk for Readmission After Resection.
JCO Clin Cancer Inform
November 2024
College of Computing and Informatics, Drexel University, Philadelphia, PA.
Purpose: Machine learning algorithms are used for predictive modeling in medicine, but studies often do not evaluate or report on the potential biases of the models. Our purpose was to develop clinical prediction models for readmission after surgery in colorectal cancer (CRC) patients and to examine their potential for racial bias.
Methods: We used the 2012-2020 American College of Surgeons' National Surgical Quality Improvement Program (ACS-NSQIP) Participant Use File and Targeted Colectomy File.
Identification of MYC and STAT3 for early diagnosis based on the long noncoding RNA-mRNA network and bioinformatics in colorectal cancer.
Front Immunol
January 2025
Department of Colorectal Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Background: Colorectal cancer (CRC) ranks among the top three cancers globally in both incidence and mortality, posing a significant public health challenge. Most CRC cases are diagnosed at intermediate to advanced stages, and reliable biomarkers for early detection are lacking. Long non-coding RNAs (lncRNAs) have been implicated in various cancers, including CRC, playing key roles in tumor development, progression, and prognosis.
View Article and Find Full Text PDFGlobal research trends on nanotechnology and colorectal cancer: a two-decade analysis.
Nanomedicine (Lond)
January 2025
Hepatopancreatobiliary Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Introduction: Colorectal cancer (CRC) remains a serious threat to humans worldwide. In this study, we used bibliometric analysis of the scientific literature to assess the trends and prospects of nanotechnology applications in CRC.
Materials And Methods: We used the Web of Science Core Collection database to screen relevant publications on nanotechnology and CRC from 2004 to 2023 based on the inclusion criteria.
Evolving Landscape of Colorectal Cancer: Global and Regional Burden, Risk Factor Dynamics, and Future Scenarios (the Global Burden of Disease 1990-2050).
Ageing Res Rev
January 2025
Northern Jiangsu People's Hospital, Clinical Teaching Hospital of Medical School, Nanjing University, Yangzhou, 225001, China; Northern Jiangsu People's Hospital, Yangzhou, China; Yangzhou Key Laboratory of Basic and Clinical Transformation of Digestive and Metabolic Disease. Electronic address:
Background: Presently, colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. We provided global, regional, and national estimates of the burden of CRC and their attributable risks from 1990 to 2021, aiming to guide screening, early detection, and treatment strategies, optimize healthcare resource allocation, and facilitate the rational management of burden of CRC.
Methods: Using data derived from the Global Burden of Disease database, we estimated the incidence, mortality, and disability-adjusted life years (DALYs) of CRC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!